APERTURE THERAPEUTICS, INC.
Oligonucleotide therapeutic targeting neuroinflammation pathways in frontotemporal dementia
- Sector
- Biotech
- Total capital
- $460K
- Federal grants
- $460K
- 1 award · 2024
- Rank in peer group#294 of 502
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 6 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Discovering targeted modulator of microglial activity as a candidate treatment for FTD and related dementias.$460K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 0 granted of 6- PendingCompositions For Modulating MMP9 Expression And Uses ThereofUSPTOApplication PCTUS2025060804
- PendingAntibody Oligonucleotide Conjugates Comprising An Antisense Polynucleotide Agent Conjugated To A CD33 Antibody And Methods Of Use ThereofUSPTOApplication PCTUS2025045099
- PendingCompositions For Modulating MMP9 Expression And Uses ThereofUSPTOApplication 63737410
Show all 6 patent records
- Compositions For Modulating MMP9 Expression And Uses ThereofApplication PCTUS2025060804Pending
- Antibody Oligonucleotide Conjugates Comprising An Antisense Polynucleotide Agent Conjugated To A CD33 Antibody And Methods Of Use ThereofApplication PCTUS2025045099Pending
- Compositions For Modulating MMP9 Expression And Uses ThereofApplication 63737410Pending
- Compositions For Modulating CD33 ExpressionApplication PCTUS2024060827Pending
- Antibody Oligonucleotide Conjugates Comprising An Antisense Polynucleotide Agent Conjugated To A CD33 Antibody And Methods Of Use ThereofApplication 63690860Pending
- Compositions For Modulating CD33 ExpressionApplication 63613551Pending
Related companies, and why
- SAB Biotherapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Atsena Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- RNA THERAPEUTICS INC.Similar federal contract value in Biotech · null in contracts
- Converge Bio Inc.Similar federal contract value in Biotech · null in contracts
- ABEOME CORPORATIONSimilar federal contract value in Biotech · null in contracts
- CELLECTAR BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .